Global Autism Diagnostic Market Growth (Status and Outlook) 2025-2031

The global Autism Diagnostic market size is predicted to grow from US$ 33100 million in 2025 to US$ 54340 million in 2031; it is expected to grow at a CAGR of 8.6% from 2025 to 2031.

Autism or autism spectrum disorder (ASD) is a mental disability characterized by challenges with social skills including impaired social behavior, speech and communication.Autism or ASD is the prevailing disabilities. Thus, the early identification, assessment, and diagnosis is the first step toward autism treatment.Autism Diagnostics Market Segmented By type that is Autistic Disorder, Asperger Syndrome and Childhood Disintegrative Disorder.

United States market for Autism Diagnostic is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for Autism Diagnostic is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for Autism Diagnostic is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Global key Autism Diagnostic players cover Pfizer, Inc., Novartis AG, Allergan, Merck&Co Inc., Eli Lilly and Company, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.

LPI (LP Information)' newest research report, the “Autism Diagnostic Industry Forecast” looks at past sales and reviews total world Autism Diagnostic sales in 2024, providing a comprehensive analysis by region and market sector of projected Autism Diagnostic sales for 2025 through 2031. With Autism Diagnostic sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Autism Diagnostic industry.

This Insight Report provides a comprehensive analysis of the global Autism Diagnostic landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Autism Diagnostic portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Autism Diagnostic market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Autism Diagnostic and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Autism Diagnostic.

This report presents a comprehensive overview, market shares, and growth opportunities of Autism Diagnostic market by product type, application, key players and key regions and countries.

Segmentation by Type:

Communication and Behavioral Therapy

Occupational Therapies

Hyperbaric Oxygen Therapy

Chelation Therapy

Oxytocin Therapy

Drug Therapies

Others

Segmentation by Application:

Autistic Disorder

Asperger Syndrome

Childhood Disintegrative Disorder

Others

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

Pfizer, Inc.

Novartis AG

Allergan

Merck&Co Inc.

Eli Lilly and Company

F. Hoffmann-La Roche Ltd.

Teva Pharmaceutical Industries Ltd.

Johnson&Johnson Services, Inc.

Bristol–Myer Squibb

Otsuka Holdings Co., Ltd.

Actavis, Inc.

Curemark LLC.

Mylan Pharmaceuticals

Asuragen Inc.

Please note: The report will take approximately 2 business days to prepare and deliver.